Clinical trial NCT07013838: The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis
Official title: Comparison of Deucravacitinib and Adalimumab for the Treatment of Relapsed Takayasu's Arteritis: The TYK-TAK Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE4
Conditions: Takayasu Arteritis (TAK)
Keywords: Deucravacitinib
Adalimumab
Relapsed
Efficacy
Safety
Takayasu arteritis
Lead sponsor: Chinese SLE Treatment And Research Group
Sponsor class: OTHER
First posted: 2025-06-10
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: prospective, single-center, randomized, open-label trial
Primary purpose: TREATMENT

Brief summary: This is a 24-week, single-center, randomized, open-label trial conducted by Peking Union Medical College Hospital. The aim of this study is to assess the efficacy and safety of deucravacitinib in adult patients with relapsing TAK in comparison to patients treated with TNF inhibitor (TNFi), the most well-recognized therapeutic choice of non-glucocorticoid immunosuppressive for patients with relapsed or refractory TAK.

Detailed description: Background:

The majority of patients with TAK experience relapses, and some patients fail to respond adequately to current medications used for treatment of TAK. There is an urgent unmet need to identify novel therapies to effectively treat TAK. Th-17 and Th-1 cells, and their related cytokines IL-12, IL-23, IL-17, and type I interferon have all been reported to play a role in the pathogenesis of TAK. Tyrosine kinase 2 (TYK2) mediates signaling transduction between these key cytokines and immune cells. Therefore, blocking TYK2 signaling may downregulate potential pathogenic pathways in TAK, and may be a therapeutic alternative. No study has investigated the effectiveness of agents targeting TYK2 in the treatment of TAK so far. In the present study, we aim to investigate whether deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, is effective and safe for patients with relapsed TAK.

Objectives:

To assess the efficacy and safety of deucravacitinib in adult patients with relapsing TAK in comparison to patients treated with TNF inhibitor (TNFi), the most well-recognized therapeutic choice of non-glucocorticoid immunosuppressive for patients with relapsed or refractory TAK.

Overall Design:

This is a 24-week, single-center, randomized, open-label trial conducted by Peking Union Medical College Hospital. Patients enrolled into the study are randomly assigned (in a 1:1 ratio, 25 patients in each group) to receive deucravacitinib or adalimumab (a TNFi). Patients are followed for efficacy and safety at month 1, month 3, and month 6. Adverse events/Serious adverse events are assessed and recorded at each visit.

Eligibility criteria: Inclusion Criteria:

* Participants are eligible to be included in the study only if all of the following criteria apply:

  1. Signed Written Informed Consent

     1. Participants fully understand the purpose, nature, method, and possible adverse reactions of the study, willing to consent to the trial and follow study protocol and sign informed consent.
     2. Participants must have signed an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written informed consent form (ICF) in accordance with regulatory, local, and institutional guidelines. This ICF must be obtained before performing any protocol related procedures that are not part of normal patient care.
  2. Type of Participant and Target Disease Characteristics

     1. Adult patients (aged 18 or older) fulfilling the 2022 ACR/EULAR classification criteria for TAK.
     2. Persistence of active disease or relapse despite treatment with GCs combined with a conventional synthetic or biologics immunosuppressive agent other than TNFi.
     3. Active vasculitis by reader interpretation of FDG-PET at enrollment (by the same reader).
  3. Reproductive Status The investigator or designee shall counsel women of childbearing potential (WOCBP) and male participants who are sexually active with WOCBP on the importance of pregnancy prevention and the implications of an unexpected pregnancy.

WOCBP must have a negative highly sensitive specify: urine or serum as required by local regulations pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin) within 24 hours prior to the start of study intervention.

A female is eligible to participate if she is not pregnant or breastfeeding and at least 1 of the following conditions applies:

Is not a WOCBP OR Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \< 1% per year) during the intervention period and for at least 5 half-lives after product administration and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction for the same period.

WOCBP and male participants who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception.

Exclusion Criteria:

* Participants are excluded from the study if any of the following criteria apply:

  1. Medical Conditions

     1. Severe disease from TAK for which urgent treatment with interventional procedures or bypass surgery is considered necessary
     2. Critical organ involvement of TAK, such as myocardial or coronary artery involvement, or cerebral ischemia
     3. Active hepatitis B or C virus infection, active tuberculosis infection
     4. Malignancy in the past 5 years (with the exception of fully excised non-melanoma skin cancer or cervical carcinoma in situ)
  2. Physical and Laboratory Test Findings

     1. Serum liver enzyme tests 3 times higher than the upper limits of normal range
     2. Estimated glomerular filtration rate ≤ 30 ml/minute
  3. Other Exclusion Criteria

     1. Females who are pregnant
     2. Ever treated with TNFi (including adalimumab) and discontinued due to inadequate response or intolerance.
     3. Any other sound medical, psychiatric, and/or social reason as determined by the investigator

Primary outcomes:
measure: Overall response rate at week 24
timeFrame: Week 24
Secondary outcomes:
measure: Time to clinical remission
timeFrame: from inclusion to the end of the study, 24 weeks in total
measure: Disease recurrence after achieving clinical remission
timeFrame: from inclusion to the end of the study, 24 weeks in total
measure: Time to disease recurrence
timeFrame: from inclusion to the end of the study, 24 weeks in total
measure: Changes in erythrocyte sedimentation rate (ESR)
timeFrame: week 4, 12 and 24
measure: Changes in serum C reactive protein (CRP)
timeFrame: week 4, 12 and 24
measure: Changes in vascular ultrasonography
timeFrame: from baseline to weeks 12 and 24
measure: Changes in PET/CT scans
timeFrame: from the baseline to week 24
measure: Change in level of cytokines
timeFrame: week 4, 12 and 24
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking Union Medical College Hospital
Study officials:
affiliation: Peking Unione Mdecial College Hospital
name: Xinping Tian, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Le AM, Puig L, Torres T. Deucravacitinib for the Treatment of Psoriatic Disease. Am J Clin Dermatol. 2022 Nov;23(6):813-822. doi: 10.1007/s40257-022-00720-0. Epub 2022 Aug 12.